Global talks on a pandemic treaty hit a snag over the Pathogen Access and Benefit-Sharing (PABS) annex. Here’s what’s at stake, what’s delaying finalisation, and what resolution could mean for rapid pathogen sharing and vaccine access. Below are common questions people search for, each answered clearly to help you understand the stakes and the next steps in these negotiations.
The Pathogen Access and Benefit-Sharing (PABS) annex is a core part of the global treaty that would govern how pathogen data and samples are shared quickly and fairly. It also outlines how benefits—like vaccines, tests, and treatments—are allocated to countries that share materials. Without PABS, the treaty risks limited access to critical tools during health emergencies and uneven sharing of data.
Negotiators remaining disputes include how to balance equity with incentives for innovation, how to compensate for shared pathogen data, and the specifics of benefit-sharing arrangements. Differences between developed and developing blocs, including positions on data sovereignty, cost-sharing, and enforcement mechanisms, continue to slow consensus.
A resolved PABS framework would aim to speed up the sharing of pathogen data and samples during outbreaks and ensure timely access to vaccines, diagnostics, and treatments for affected countries. It would reduce delays, promote transparency, and align incentives so countries feel supported to participate in rapid sharing without bearing excessive burdens.
Timing is uncertain and depends on ongoing negotiations. Observers point to the possibility of new sessions or deadlines after recent deadlocks, but exact dates can shift. If talks progress, a breakthrough could come from a narrower set of agreed principles or compromise language that satisfies both blocs about data sharing and benefit distribution.
The main treaty framework was adopted in May 2025, but the PABS annex sits outside that core package and requires separate consensus. This separation means even after the main treaty is launched, detailed rules on pathogen sharing and benefit allocation need further agreement, causing a delay in full entry into force.
Until PABS is resolved, some mechanisms for rapid sharing and guaranteed access to vaccines and treatments may remain informal or incomplete. This can slow collective responses, especially for low- and middle-income countries that rely on clear, binding rules to ensure timely access to essential tools during health emergencies.
Finalisation of pact governing global response to disease outbreaks delayed as talks on how to share benefits stall